Literature DB >> 26929325

Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome.

Satyendra C Tripathi1, Haley L Peters2, Ayumu Taguchi3, Hiroyuki Katayama1, Hong Wang1, Amin Momin1, Mohit Kumar Jolly4, Muge Celiktas1, Jaime Rodriguez-Canales3, Hui Liu3, Carmen Behrens3, Ignacio I Wistuba3, Eshel Ben-Jacob4, Herbert Levine5, Jeffrey J Molldrem2, Samir M Hanash1, Edwin J Ostrin6.   

Abstract

The immunoproteasome plays a key role in generation of HLA peptides for T cell-mediated immunity. Integrative genomic and proteomic analysis of non-small cell lung carcinoma (NSCLC) cell lines revealed significantly reduced expression of immunoproteasome components and their regulators associated with epithelial to mesenchymal transition. Low expression of immunoproteasome subunits in early stage NSCLC patients was associated with recurrence and metastasis. Depleted repertoire of HLA class I-bound peptides in mesenchymal cells deficient in immunoproteasome components was restored with either IFNγ or 5-aza-2'-deoxycytidine (5-aza-dC) treatment. Our findings point to a mechanism of immune evasion of cells with a mesenchymal phenotype and suggest a strategy to overcome immune evasion through induction of the immunoproteasome to increase the cellular repertoire of HLA class I-bound peptides.

Entities:  

Keywords:  EMT; NSCLC; immunoproteasome; immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 26929325      PMCID: PMC4801290          DOI: 10.1073/pnas.1521812113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  50 in total

1.  Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules.

Authors:  Danielle de Verteuil; Tara L Muratore-Schroeder; Diana P Granados; Marie-Hélène Fortier; Marie-Pierre Hardy; Alexandre Bramoullé; Etienne Caron; Krystel Vincent; Sylvie Mader; Sébastien Lemieux; Pierre Thibault; Claude Perreault
Journal:  Mol Cell Proteomics       Date:  2010-05-19       Impact factor: 5.911

2.  Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation.

Authors:  Jacques Chapiro; Stéphane Claverol; Fanny Piette; Wenbin Ma; Vincent Stroobant; Benoît Guillaume; Jean-Edouard Gairin; Sandra Morel; Odile Burlet-Schiltz; Bernard Monsarrat; Thierry Boon; Benoît J Van den Eynde
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

3.  Cancer immunology.

Authors:  Cornelis J M Melief; Olivera J Finn
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

4.  Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.

Authors:  Intissar Akalay; Bassam Janji; Meriem Hasmim; Muhammad Zaeem Noman; Fabrice André; Patricia De Cremoux; Philippe Bertheau; Cécile Badoual; Philippe Vielh; Annette K Larsen; Michèle Sabbah; Tuan Zea Tan; Joan Herr Keira; Nicole Tsang Ying Hung; Jean Paul Thiery; Fathia Mami-Chouaib; Salem Chouaib
Journal:  Cancer Res       Date:  2013-02-22       Impact factor: 12.701

Review 5.  Emerging roles of immunoproteasomes beyond MHC class I antigen processing.

Authors:  Frédéric Ebstein; Peter-Michael Kloetzel; Elke Krüger; Ulrike Seifert
Journal:  Cell Mol Life Sci       Date:  2012-03-02       Impact factor: 9.261

Review 6.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

7.  Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons.

Authors:  Jian Feng; Yu Zhou; Susan L Campbell; Thuc Le; En Li; J David Sweatt; Alcino J Silva; Guoping Fan
Journal:  Nat Neurosci       Date:  2010-03-14       Impact factor: 24.884

8.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells.

Authors:  Suyun Huang; Corazon D Bucana; Melissa Van Arsdall; Isaiah J Fidler
Journal:  Oncogene       Date:  2002-04-11       Impact factor: 9.867

9.  HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.

Authors:  Menghong Sun; Carmen Behrens; Lei Feng; Natalie Ozburn; Ximing Tang; Guosheng Yin; Ritsuko Komaki; Marileila Varella-Garcia; Waun Ki Hong; Kenneth D Aldape; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

10.  Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells.

Authors:  Weibo Luo; Gregg L Semenza
Journal:  Oncotarget       Date:  2011-07
View more
  72 in total

Review 1.  How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy.

Authors:  Jinyang Li; Ben Z Stanger
Journal:  Cancer Res       Date:  2020-06-18       Impact factor: 12.701

Review 2.  Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.

Authors:  Niki Karachaliou; Manuel Fernandez-Bruno; Jillian Wilhelmina Paulina Bracht; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

3.  Stochastic modeling of tumor progression and immune evasion.

Authors:  Jason T George; Herbert Levine
Journal:  J Theor Biol       Date:  2018-09-12       Impact factor: 2.691

4.  Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.

Authors:  Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-20

5.  Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.

Authors:  Juergen Kast
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

6.  Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric.

Authors:  Jason T George; Mohit Kumar Jolly; Shengnan Xu; Jason A Somarelli; Herbert Levine
Journal:  Cancer Res       Date:  2017-09-25       Impact factor: 12.701

7.  Anticipating critical transitions in epithelial-hybrid-mesenchymal cell-fate determination.

Authors:  Sukanta Sarkar; Sudipta Kumar Sinha; Herbert Levine; Mohit Kumar Jolly; Partha Sharathi Dutta
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-16       Impact factor: 11.205

8.  Transcription factor SPZ1 may promote TWIST-mediated epithelial-mesenchymal transition in thoracic malignancies.

Authors:  Masayuki Watanabe
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 9.  The combination of checkpoint immunotherapy and targeted therapy in cancer.

Authors:  Niki Karachaliou; Maria Gonzalez-Cao; Aaron Sosa; Jordi Berenguer; Jillian Wilhelmina Paulina Bracht; Masaoki Ito; Rafael Rosell
Journal:  Ann Transl Med       Date:  2017-10

Review 10.  Antigen processing and immune regulation in the response to tumours.

Authors:  Emma Reeves; Edward James
Journal:  Immunology       Date:  2016-10-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.